As previously described, the VEGF-C/VEGFR-3 pathway acts as an enhancer of ovarian cancer progression through autocrine and paracrine mechanisms, hence offering a potential target for therapeutic interventions [9]. Here, FLT4 is linked to ovarian carcinoma.